Meldonium (Mildronate) – Kodiac biolabs

Plain-language summaryIntrigue 68 / 100

Meldonium (Mildronate) is a Latvian-developed compound that inhibits carnitine biosynthesis, shifting cellular metabolism toward glucose-based energy. It is used for ischemic conditions in Eastern Europe. Famous for the 2016 Maria Sharapova doping case. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature Soviet-era cardioprotective with real mechanism but geographically siloed evidence base

Look, meldonium is not a boring compound. It’s just a mature one. Ivars Kalvins synthesized it at the Latvian Institute of Organic Synthesis in the 1970s as a structural analog of gamma-butyrobetaine, and the core idea is genuinely elegant: competitively inhibit gamma-butyrobetaine hydroxylase, suppress endogenous carnitine biosynthesis, and force cardiac and skeletal muscle to shift from fatty acid oxidation toward glucose oxidation. Under ischemic conditions that shift matters because glucose oxidation is more oxygen-efficient per ATP generated, and fatty acid oxidation generates disproportionate reactive oxygen species when oxygen delivery is compromised. That’s not trivial pharmacology. We like the mechanism more than we like the evidence base.

The WADA ban in 2016 and the Sharapova case turned meldonium into a household name, and it did generate a burst of Western interest. But most of what we know about clinical efficacy still comes from Latvian, Russian, and Baltic cooperative trials, and the methodological standards of that literature vary substantially. Systematic reviews, including work from Karelis and colleagues trying to contextualize the WADA decision, have noted how difficult it is to evaluate the cardiac endpoint data against contemporary trial design standards. Thats a problem for any serious evidence weighting. The approved indications in Latvia and Russia are real, but regulatory approval in those markets reflects a different evidentiary threshold than FDA or EMA review.

Where meldonium still holds some bench value is metabolic research. If you’re building models of carnitine-dependent fatty acid import into mitochondria, or studying the interplay between FAO and glucose oxidation under hypoxic stress, meldonium is a reasonably clean pharmacological tool. It’s not perfect. The carnitine depletion it drives can produce off-target effects over longer exposure windows, and dosing dynamics in rodent models don’t translate cleanly to primate physiology. But as a probe of the gamma-butyrobetaine hydroxylase axis specifically, it doesn’t have many competitors.

The neuroprotection angle is worth watching. Some investigators have framed the cerebrovascular indication as a glucose-oxidation story in neural tissue, and there are a few small trials in cognitive decline populations in Eastern Europe that warrant scrutiny. We think this is the most underexplored corner of the meldonium literature in Western research contexts, but the evidence there is even thinner than the cardiac data.

Honestly, the compound sits in a frustrating middle zone. The mechanism is real, the human signal is real, and the tool utility is genuine. But five decades of development in a geographically restricted research ecosystem, with weak replication outside that ecosystem, keeps it off the frontier. If you’re already running a metabolic cardioprotection or hypoxia-response program, meldonium deserves a place in your reference pharmacology. As a primary research focus right now? The case is harder to make.

Novelty: 22
Mechanism promise: 40
In-category differentiation: 48
Evidence quality: 47
Translational signal: 50
Research bench value: 42

Rationale Meldonium scores modestly because it’s a 1970s compound with a clean, well-characterized mechanism that’s genuinely interesting for ischemia and metabolic research, but the evidence base is overwhelmingly concentrated in Latvian and Russian institutions with minimal Western replication, and the clinical indication space it targets is crowded with better-validated alternatives. The WADA notoriety brought attention but not new mechanistic depth.

Carnitine biosynthesis inhibitor

A Latvian-developed carnitine biosynthesis inhibitor used clinically for ischemic heart disease, banned by WADA in 2016 after high-profile athlete cases.

Abstract

Meldonium (Mildronate; 3-(2,2,2-trimethylhydrazinium)propionate; CAS 76144-81-5; molecular formula C6H14N2O2; molecular weight 146.19) is a synthetic structural analog of gamma-butyrobetaine, the precursor of L-carnitine, developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. The compound competitively inhibits gamma-butyrobetaine hydroxylase, reducing endogenous carnitine biosynthesis and shifting cardiac and skeletal muscle metabolism from fatty acid oxidation toward glucose oxidation. The metabolic shift is theoretically protective under ischemic conditions where fatty acid oxidation generates increased reactive oxygen species. Meldonium is approved in Latvia, Russia, and several former Soviet states for ischemic heart disease, chronic heart failure, and cognitive symptoms of cerebrovascular insufficiency. The compound was added to the WADA prohibited list in 2016 after widespread use in elite athletes; the Maria Sharapova case is the most prominent. Pharmacokinetics: plasma half-life 3 to 6 hours; oral bioavailability 78 percent; renally excreted. Doses are 500 to 1000 mg per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-066Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.